Skip to main content
. Author manuscript; available in PMC: 2013 Jun 14.
Published in final edited form as: Mol Cancer Ther. 2012 Aug 9;11(10):2301–2305. doi: 10.1158/1535-7163.MCT-12-0511

Figure 1. A breast tumor harboring mutant KRAS does not demonstrate molecular endocrine resistance.

Figure 1

A) Chemical structure of letrozole B) Sanger sequencing traces of KRAS codon 12 in the left and right bilateral tumors, before and after 2 weeks of letrozole therapy. C) Plot of Ki67 scores in left and right breast tumors before and after 2 weeks of letrozole therapy. Ki67 IHC was scored by 3 blinded independent pathologists to account for variability in scoring. Bars represent mean ± s.d. D) Representative IHC of Ki67 in left and right breast tumors before and after 2 weeks of letrozole therapy.